← back to search

Michael C. Keefer

University of Rochester · US
Area of research
Virology · Immunology
Research interest
Research interests include HIV Research and Treatment, Immune Cell Function and Interaction, Immunotherapy and Immune Responses, and HIV/AIDS Research and Interventions.
h-index
44
citations
5,480
works
147
NIH funding
primary concept
Medicine
email

Recent publications

Vaccination with mRNA-encoded membrane-anchored HIV envelope trimers elicited tier 2 neutralizing antibodies in a phase 1 clinical trial
Science Translational Medicine 2025cited by 23position: middledoi
High Frequency of Chronic Urticaria Following an Investigational HIV-1 BG505 MD39.3 Trimer mRNA Vaccine in a Phase 1, Randomized, Open-Label Clinical Trial (HVTN 302)
Annals of Internal Medicine 2025cited by 11position: middledoi
A polyvalent DNA prime with matched polyvalent protein/GLA-SE boost regimen elicited the most robust and broad IgG and IgG3 V1V2 binding antibody and CD4+ T cell responses among 13 HIV vaccine trials
Emerging Microbes & Infections 2025cited by 4position: middledoi
Predictors of HIV rebound differ by timing of antiretroviral therapy initiation
JCI Insight 2024cited by 26position: middledoi
Use of 3M-052-AF with Alum adjuvant in HIV trimer vaccine induces human autologous neutralizing antibodies
The Journal of Experimental Medicine 2024cited by 26position: middledoi
Safety and immunogenicity of a polyvalent DNA–protein HIV vaccine with matched Env immunogens delivered as a prime–boost regimen or coadministered in HIV-uninfected adults in the USA (HVTN 124): a phase 1, placebo-controlled, double-blind randomised controlled trial
The Lancet HIV 2024cited by 10position: middledoi
Safety and Immunogenicity of Ad26-Vectored HIV Vaccine With Mosaic Immunogens and a Novel Mosaic Envelope Protein in HIV-Uninfected Adults: A Phase 1/2a Study
The Journal of Infectious Diseases 2022cited by 34position: middledoi
Baseline host determinants of robust human HIV-1 vaccine-induced immune responses: A meta-analysis of 26 vaccine regimens
EBioMedicine 2022cited by 13position: middledoi
Safety and immunogenicity of SARS-CoV-2 recombinant protein vaccine formulations in healthy adults: interim results of a randomised, placebo-controlled, phase 1–2, dose-ranging study
The Lancet Infectious Diseases 2021cited by 123position: middledoi
Time to Viral Rebound After Interruption of Modern Antiretroviral Therapies
Clinical Infectious Diseases 2021cited by 92position: middledoi
Assessment of Coronary Artery Disease With Computed Tomography Angiography and Inflammatory and Immune Activation Biomarkers Among Adults With HIV Eligible for Primary Cardiovascular Prevention
JAMA Network Open 2021cited by 78position: middledoi
Safety and immunogenicity of two heterologous HIV vaccine regimens in healthy, HIV-uninfected adults (TRAVERSE): a randomised, parallel-group, placebo-controlled, double-blind, phase 1/2a study
The Lancet HIV 2020cited by 91position: middledoi
Robust antibody and cellular responses induced by DNA-only vaccination for HIV
JCI Insight 2020cited by 47position: middledoi
Intramuscular and Intradermal Electroporation of HIV-1 PENNVAX-GP® DNA Vaccine and IL-12 Is Safe, Tolerable, Acceptable in Healthy Adults
Vaccines 2020cited by 27position: middledoi
The Emperor’s New Clothes: PRospective Observational Evaluation of the Association Between Initial VancomycIn Exposure and Failure Rates Among ADult HospitalizEd Patients With Methicillin-resistant Staphylococcus aureus Bloodstream Infections (PROVIDE)
Clinical Infectious Diseases 2019cited by 157position: middledoi
Fc Gamma Receptor Polymorphisms Modulated the Vaccine Effect on HIV-1 Risk in the HVTN 505 HIV Vaccine Trial
Journal of Virology 2019cited by 31position: middledoi
Broad and Protective Influenza B Virus Neuraminidase Antibodies in Humans after Vaccination and their Clonal Persistence as Plasma Cells
mBio 2019cited by 28position: middledoi
Reducing the African American HIV Disease Burden in the Deep South: Addressing the Role of Faith and Spirituality
AIDS and Behavior 2019cited by 20position: middledoi
A Highly Potent and Broadly Neutralizing H1 Influenza-Specific Human Monoclonal Antibody
Scientific Reports 2018cited by 69position: middledoi
Modification of the Association Between T-Cell Immune Responses and Human Immunodeficiency Virus Type 1 Infection Risk by Vaccine-Induced Antibody Responses in the HVTN 505 Trial
The Journal of Infectious Diseases 2018cited by 44position: middledoi
Higher T-Cell Responses Induced by DNA/rAd5 HIV-1 Preventive Vaccine Are Associated With Lower HIV-1 Infection Risk in an Efficacy Trial
The Journal of Infectious Diseases 2017cited by 75position: middledoi
Diversion of HIV-1 vaccine–induced immunity by gp41-microbiota cross-reactive antibodies
Science 2015cited by 202position: middledoi
Vaccination With Heterologous HIV-1 Envelope Sequences and Heterologous Adenovirus Vectors Increases T-Cell Responses to Conserved Regions: HVTN 083
The Journal of Infectious Diseases 2015cited by 25position: middledoi
Specificity and 6-Month Durability of Immune Responses Induced by DNA and Recombinant Modified Vaccinia Ankara Vaccines Expressing HIV-1 Virus-Like Particles
The Journal of Infectious Diseases 2014cited by 84position: middledoi
Efficacy Trial of a DNA/rAd5 HIV-1 Preventive Vaccine
New England Journal of Medicine 2013cited by 584position: middledoi
Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery
The Journal of Infectious Diseases 2013cited by 196position: middledoi

Grants

University of Rochester HIV/AIDS Clinical Trials Unit Administrative Supplement
NIH3UM1AI069511-19S1$1,094,7092025–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH3UM1AI069511-14S1$290,5192020–2020Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-20$1,959,8802007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-16$1,892,5372007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-18$1,831,0852007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-19$1,817,3832007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH2UM1AI069511-15$1,762,4952007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-17$1,757,9542007–2027Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-13$1,633,6862007–2020Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-14$1,515,6642007–2020Contact PIRePORTER
University of Rochester HIV/AIDS Clinical Trials Unit
NIH5UM1AI069511-12$1,166,4212007–2020Contact PIRePORTER

Frequent collaborators

Paul A. Goepfert · University of Alabama at Birmingham4 papers (2014–2025)Georgia D. Tomaras · International Vaccine Institute4 papers (2014–2024)Ian Frank · Future University Hakodate4 papers (2019–2025)M. Juliana McElrath · Fred Hutch Cancer Center4 papers (2014–2025) · 3 papers (2014–2024)Susan Buchbinder · University of California System3 papers (2014–2022)James G. Kublin · Fred Hutch Cancer Center3 papers (2020–2025)James J. Kobie · University of Alabama at Birmingham3 papers (2018–2022)Lawrence Corey · Infectious Disease Research Institute3 papers (2020–2025)Alexander F. Rosenberg · University of Alabama at Birmingham2 papers (2018–2019)David C. Montefiori · Duke University2 papers (2014–2024)Yunda Huang · Fred Hutch Cancer Center2 papers (2020–2022)Kristen W. Cohen · Duke University2 papers (2019–2022)Marnie Elizaga · Seattle University2 papers (2014–2020)Srilatha Edupuganti · Emory University2 papers (2020–2022)Mary Allen · University of Colorado Boulder2 papers (2024–2025)Michael Pensiero · National Institute of Allergy and Infectious Diseases2 papers (2014–2024)Janine Maenza · Seattle University2 papers (2020–2025)Christopher Fucile · University of Alabama at Birmingham2 papers (2018–2019)Guido Ferrari · Duke University2 papers (2019–2024)